by: Parent Project Muscular Dystrophy
Last week Sarepta Therapeutics joined PPMD to discuss ENVISION, their upcoming 18-month placebo-controlled Phase 3 study of SRP-9001 (delandistrogene moxeparvovec) for older ambulatory and non-ambulatory individuals with Duchenne. Matthew Furgerson, PhD, Medical Director, Clinical Development and Teji Singh, MD, Vice President, Head of Clinical Development discussed the design of the Phase 3 clinical trial, including certain geographical exclusions for the two cohorts. Sarepta also shared current plans for broadening access such as their future expansion to younger patients in the ENVOL study and investigations around overcoming pre-existing antibodies.
If you missed the live event, the recording can be found below.
